睡眠呼吸暂停治疗药研发商Apnimed在扩大IPO规模后，即将迎来上市首日股价大涨

路透中文07-31 23:32

BUZZ-睡眠呼吸暂停治疗药研发商<a href="https://laohu8.com/S/APMD">Apnimed</a>在扩大IPO规模后，即将迎来上市首日股价大涨

7月31日 - ** 处于后期研发阶段的生物技术公司Apnimed APMD.O 在IPO定价超出目标后，有望于本周五在纳斯达克上市首日股价大涨

** APMD股价最新显示开盘价将达22美元，远高于16美元的发行价

** 这家总部位于马萨诸塞州剑桥市的公司于周四晚间售出1200万股 (link) 股票，筹资1.92亿美元

** 该公司此前曾计划以每股14至16美元的价格发行1000万股

** 其唯一的临床候选产品AD109（Oxnimbi）是一种每日一次、于夜间服用的口服药，用于治疗阻塞性睡眠呼吸暂停（OSA），该病症表现为睡眠期间气道反复塌陷，导致血氧水平下降并干扰呼吸

** 根据招股说明书，Morningside、Alpha Wave Ventures 以及日本制药公司盐野义制药 4507.T 是该公司的最大股东 (link)

** 美银、Evercore、Cantor Fitzgerald和LifeSci Capital担任此次IPO的联合簿记管理人

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2655601933?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-07-31 23:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655601933","market":"us","top_or_hot":-1,"title":"睡眠呼吸暂停治疗药研发商Apnimed在扩大IPO规模后，即将迎来上市首日股价大涨","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-睡眠呼吸暂停治疗药研发商<a href=\"https://laohu8.com/S/APMD\">Apnimed</a>在扩大IPO规模后，即将迎来上市首日股价大涨</title></head><body><p><span>7月31日</span><span> - </span>** 处于后期研发阶段的<a href=\"https://laohu8.com/S/000504\">生物</a>技术公司Apnimed <span>APMD.O</span> 在IPO定价超出目标后，有望于本周五在纳斯达克上市首日股价大涨</p><p>** APMD股价最新显示开盘价将达22美元，远高于16美元的发行价</p><p>** 这家总部位于马萨诸塞州剑桥市的公司于周四晚间售出1200万股 (link) 股票，筹资1.92亿美元</p><p>** 该公司此前曾计划以每股14至16美元的价格发行1000万股</p><p>** 其唯一的临床候选产品AD109（Oxnimbi）是一种每日一次、于夜间服用的口服药，用于治疗阻塞性睡眠呼吸暂停（OSA），该病症表现为睡眠期间气道反复塌陷，导致血氧水平下降并干扰呼吸</p><p>** 根据招股说明书，Morningside、Alpha Wave Ventures 以及日本制药公司盐野义制药 <span>4507.T</span> 是该公司的最大股东 (link)</p><p>** 美银、<a href=\"https://laohu8.com/S/EVR\">Evercore</a>、Cantor Fitzgerald和LifeSci Capital担任此次IPO的联合簿记管理人</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>睡眠呼吸暂停治疗药研发商Apnimed在扩大IPO规模后，即将迎来上市首日股价大涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n睡眠呼吸暂停治疗药研发商Apnimed在扩大IPO规模后，即将迎来上市首日股价大涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-07-31 23:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-睡眠呼吸暂停治疗药研发商<a href=\"https://laohu8.com/S/APMD\">Apnimed</a>在扩大IPO规模后，即将迎来上市首日股价大涨</title></head><body><p><span>7月31日</span><span> - </span>** 处于后期研发阶段的<a href=\"https://laohu8.com/S/000504\">生物</a>技术公司Apnimed <span>APMD.O</span> 在IPO定价超出目标后，有望于本周五在纳斯达克上市首日股价大涨</p><p>** APMD股价最新显示开盘价将达22美元，远高于16美元的发行价</p><p>** 这家总部位于马萨诸塞州剑桥市的公司于周四晚间售出1200万股 (link) 股票，筹资1.92亿美元</p><p>** 该公司此前曾计划以每股14至16美元的价格发行1000万股</p><p>** 其唯一的临床候选产品AD109（Oxnimbi）是一种每日一次、于夜间服用的口服药，用于治疗阻塞性睡眠呼吸暂停（OSA），该病症表现为睡眠期间气道反复塌陷，导致血氧水平下降并干扰呼吸</p><p>** 根据招股说明书，Morningside、Alpha Wave Ventures 以及日本制药公司盐野义制药 <span>4507.T</span> 是该公司的最大股东 (link)</p><p>** 美银、<a href=\"https://laohu8.com/S/EVR\">Evercore</a>、Cantor Fitzgerald和LifeSci Capital担任此次IPO的联合簿记管理人</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APMD","symbol_name":"Apnimed","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL4T43X1X7:1","article_id":"2655601933","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2655601933","pubTimestamp":1785511947,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-睡眠呼吸暂停治疗药研发商Apnimed在扩大IPO规模后，即将迎来上市首日股价大涨7月31日-** 处于后期研发阶段的生物技术公司ApnimedAPMD.O在IPO定价超出目标后，有望于本周五在纳斯达克上市首日股价大涨** APMD股价最新显示开盘价将达22美元，远高于16美元的发行价** 这家总部位于马萨诸塞州剑桥市的公司于周四晚间售出1200万股 (link) 股票，筹资1.92亿美","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"APMD":"Apnimed","BK4127":"投资银行业与经纪业","EVR":"Evercore"},"translate_title":"Apnimed, a developer of sleep apnea therapy drugs, is about to usher in the first day of listing after expanding its IPO scale","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APMD":0.9,"EVR":0.9},"content_text":"BUZZ-睡眠呼吸暂停治疗药研发商<a href=\"https://laohu8.com/S/APMD\">Apnimed</a>在扩大IPO规模后，即将迎来上市首日股价大涨7月31日 - ** 处于后期研发阶段的生物技术公司Apnimed APMD.O 在IPO定价超出目标后，有望于本周五在纳斯达克上市首日股价大涨** APMD股价最新显示开盘价将达22美元，远高于16美元的发行价** 这家总部位于马萨诸塞州剑桥市的公司于周四晚间售出1200万股 (link) 股票，筹资1.92亿美元** 该公司此前曾计划以每股14至16美元的价格发行1000万股** 其唯一的临床候选产品AD109（Oxnimbi）是一种每日一次、于夜间服用的口服药，用于治疗阻塞性睡眠呼吸暂停（OSA），该病症表现为睡眠期间气道反复塌陷，导致血氧水平下降并干扰呼吸** 根据招股说明书，Morningside、Alpha Wave Ventures 以及日本制药公司盐野义制药 4507.T 是该公司的最大股东 (link)** 美银、Evercore、Cantor Fitzgerald和LifeSci Capital担任此次IPO的联合簿记管理人","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2655601933","isCrawlerRequest":true}